Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis

Borbála Kiss, Magdolna Szántó, Csaba Hegedűs, Dóra Antal, Annamária Szödényi, Judit Márton, Gábor Méhes, László Virág, Andrea Szegedi, Péter Bai

Research output: Contribution to journalArticle

Abstract

Poly(ADP-ribose) polymerase-1 (PARP1) is a pro-inflammatory protein, whose pro-inflammatory properties were demonstrated in human. The pro-inflammatory properties of PARP1 were shown in Th1- and Th2-mediated inflammatory pathologies, but not Th17-mediated inflammation. Thus, we studied the role of PARP1 in the imiquimod-induced model of psoriasis. To our surprise, in imiquimod-induced psoriasis, PARP1 acted as an anti-inflammatory factor and its genetic deletion exacerbated symptoms. We showed that in the absence of PARP1, the epidermis thickened and the number of TUNEL-positive cells decreased in the epidermis. These data indicate programmed cell death is decreased in keratinocytes. Changes in involucrin expression suggest that keratinocyte differentiation is hampered. Furthermore, epidermal expression of IL6 increased in the psoriasiform lesions of PARP1 knockout mice, suggesting that the inflammatory response is also derailed in the absence of PARP1. Finally, we showed that PARP1 expression is reduced in human psoriatic lesions compared with control skin samples. In imiquimod-treated HPV-KER keratinocytes, PARP inhibition recapitulated the in vivo findings, namely keratinocyte hyperproliferation; furthermore, the mRNA expression of psoriasis-associated cytokines (IL6, IL1β, IL8, IL17 and IL23A) was also induced. The inhibition of TRPV1 abrogated the effects of the combined imiquimod + PARP inhibitor treatment.

Original languageEnglish
JournalExperimental Dermatology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

imiquimod
Poly(ADP-ribose) Polymerases
Psoriasis
Inflammation
Keratinocytes
Epidermis
Interleukin-6
Poly (ADP-Ribose) Polymerase-1
In Situ Nick-End Labeling
Pathology
Cell death
Interleukin-8
Knockout Mice
Skin
Cell Death
Anti-Inflammatory Agents

Keywords

  • ARTD1
  • imiquimod
  • keratinocyte differentiation
  • PARP1
  • psoriasis

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis. / Kiss, Borbála; Szántó, Magdolna; Hegedűs, Csaba; Antal, Dóra; Szödényi, Annamária; Márton, Judit; Méhes, Gábor; Virág, László; Szegedi, Andrea; Bai, Péter.

In: Experimental Dermatology, 01.01.2019.

Research output: Contribution to journalArticle

@article{ec9ed9550fbb4115b4f85adce5758829,
title = "Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis",
abstract = "Poly(ADP-ribose) polymerase-1 (PARP1) is a pro-inflammatory protein, whose pro-inflammatory properties were demonstrated in human. The pro-inflammatory properties of PARP1 were shown in Th1- and Th2-mediated inflammatory pathologies, but not Th17-mediated inflammation. Thus, we studied the role of PARP1 in the imiquimod-induced model of psoriasis. To our surprise, in imiquimod-induced psoriasis, PARP1 acted as an anti-inflammatory factor and its genetic deletion exacerbated symptoms. We showed that in the absence of PARP1, the epidermis thickened and the number of TUNEL-positive cells decreased in the epidermis. These data indicate programmed cell death is decreased in keratinocytes. Changes in involucrin expression suggest that keratinocyte differentiation is hampered. Furthermore, epidermal expression of IL6 increased in the psoriasiform lesions of PARP1 knockout mice, suggesting that the inflammatory response is also derailed in the absence of PARP1. Finally, we showed that PARP1 expression is reduced in human psoriatic lesions compared with control skin samples. In imiquimod-treated HPV-KER keratinocytes, PARP inhibition recapitulated the in vivo findings, namely keratinocyte hyperproliferation; furthermore, the mRNA expression of psoriasis-associated cytokines (IL6, IL1β, IL8, IL17 and IL23A) was also induced. The inhibition of TRPV1 abrogated the effects of the combined imiquimod + PARP inhibitor treatment.",
keywords = "ARTD1, imiquimod, keratinocyte differentiation, PARP1, psoriasis",
author = "Borb{\'a}la Kiss and Magdolna Sz{\'a}nt{\'o} and Csaba Hegedűs and D{\'o}ra Antal and Annam{\'a}ria Sz{\"o}d{\'e}nyi and Judit M{\'a}rton and G{\'a}bor M{\'e}hes and L{\'a}szl{\'o} Vir{\'a}g and Andrea Szegedi and P{\'e}ter Bai",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/exd.14061",
language = "English",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis

AU - Kiss, Borbála

AU - Szántó, Magdolna

AU - Hegedűs, Csaba

AU - Antal, Dóra

AU - Szödényi, Annamária

AU - Márton, Judit

AU - Méhes, Gábor

AU - Virág, László

AU - Szegedi, Andrea

AU - Bai, Péter

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Poly(ADP-ribose) polymerase-1 (PARP1) is a pro-inflammatory protein, whose pro-inflammatory properties were demonstrated in human. The pro-inflammatory properties of PARP1 were shown in Th1- and Th2-mediated inflammatory pathologies, but not Th17-mediated inflammation. Thus, we studied the role of PARP1 in the imiquimod-induced model of psoriasis. To our surprise, in imiquimod-induced psoriasis, PARP1 acted as an anti-inflammatory factor and its genetic deletion exacerbated symptoms. We showed that in the absence of PARP1, the epidermis thickened and the number of TUNEL-positive cells decreased in the epidermis. These data indicate programmed cell death is decreased in keratinocytes. Changes in involucrin expression suggest that keratinocyte differentiation is hampered. Furthermore, epidermal expression of IL6 increased in the psoriasiform lesions of PARP1 knockout mice, suggesting that the inflammatory response is also derailed in the absence of PARP1. Finally, we showed that PARP1 expression is reduced in human psoriatic lesions compared with control skin samples. In imiquimod-treated HPV-KER keratinocytes, PARP inhibition recapitulated the in vivo findings, namely keratinocyte hyperproliferation; furthermore, the mRNA expression of psoriasis-associated cytokines (IL6, IL1β, IL8, IL17 and IL23A) was also induced. The inhibition of TRPV1 abrogated the effects of the combined imiquimod + PARP inhibitor treatment.

AB - Poly(ADP-ribose) polymerase-1 (PARP1) is a pro-inflammatory protein, whose pro-inflammatory properties were demonstrated in human. The pro-inflammatory properties of PARP1 were shown in Th1- and Th2-mediated inflammatory pathologies, but not Th17-mediated inflammation. Thus, we studied the role of PARP1 in the imiquimod-induced model of psoriasis. To our surprise, in imiquimod-induced psoriasis, PARP1 acted as an anti-inflammatory factor and its genetic deletion exacerbated symptoms. We showed that in the absence of PARP1, the epidermis thickened and the number of TUNEL-positive cells decreased in the epidermis. These data indicate programmed cell death is decreased in keratinocytes. Changes in involucrin expression suggest that keratinocyte differentiation is hampered. Furthermore, epidermal expression of IL6 increased in the psoriasiform lesions of PARP1 knockout mice, suggesting that the inflammatory response is also derailed in the absence of PARP1. Finally, we showed that PARP1 expression is reduced in human psoriatic lesions compared with control skin samples. In imiquimod-treated HPV-KER keratinocytes, PARP inhibition recapitulated the in vivo findings, namely keratinocyte hyperproliferation; furthermore, the mRNA expression of psoriasis-associated cytokines (IL6, IL1β, IL8, IL17 and IL23A) was also induced. The inhibition of TRPV1 abrogated the effects of the combined imiquimod + PARP inhibitor treatment.

KW - ARTD1

KW - imiquimod

KW - keratinocyte differentiation

KW - PARP1

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85076365807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076365807&partnerID=8YFLogxK

U2 - 10.1111/exd.14061

DO - 10.1111/exd.14061

M3 - Article

C2 - 31755591

AN - SCOPUS:85076365807

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

ER -